Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE OpenBruce E. Sands, Chinyu Su, Alessandro Armuzzi et al.|Alimentary Pharmacology & Therapeutics|2019Cited by 85
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Mary Ellen Frustaci, Kitty Y. Wan et al.|The Lancet|2025Cited by 44
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical ProgramGary R. Lichtenstein, Edward V. Loftus, Brian Bressler et al.|Inflammatory Bowel Diseases|2022Cited by 39
EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIESRemo Panaccione, Bruce E. Sands, Silvio Danese et al.|Gastroenterology|2024Cited by 28
P516 Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trialsJulián Panés, Chunyan Su, J F Colombel et al.|Journal of Crohn s and Colitis|2018Cited by 7